MX2023013483A - Conjugados blanco del receptor de folato con enlazadores escindibles por la enzima de la membrana en cepillo, y metodos de uso en imagenologia y tratamiento de cancer. - Google Patents
Conjugados blanco del receptor de folato con enlazadores escindibles por la enzima de la membrana en cepillo, y metodos de uso en imagenologia y tratamiento de cancer.Info
- Publication number
- MX2023013483A MX2023013483A MX2023013483A MX2023013483A MX2023013483A MX 2023013483 A MX2023013483 A MX 2023013483A MX 2023013483 A MX2023013483 A MX 2023013483A MX 2023013483 A MX2023013483 A MX 2023013483A MX 2023013483 A MX2023013483 A MX 2023013483A
- Authority
- MX
- Mexico
- Prior art keywords
- folate receptor
- imagenology
- conjugates
- cancer
- white
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/481—Diagnostic techniques involving the use of contrast agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188910P | 2021-05-14 | 2021-05-14 | |
| US202263318463P | 2022-03-10 | 2022-03-10 | |
| PCT/US2022/029292 WO2022241279A2 (en) | 2021-05-14 | 2022-05-13 | Folate receptor-targeted conjugates with brush border membrane enzyme-cleavable linkers and methods of use in imaging and treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013483A true MX2023013483A (es) | 2024-02-27 |
Family
ID=84028534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013483A MX2023013483A (es) | 2021-05-14 | 2022-05-13 | Conjugados blanco del receptor de folato con enlazadores escindibles por la enzima de la membrana en cepillo, y metodos de uso en imagenologia y tratamiento de cancer. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240335570A1 (https=) |
| EP (1) | EP4337265A4 (https=) |
| JP (1) | JP2024518097A (https=) |
| AU (1) | AU2022271866A1 (https=) |
| CA (1) | CA3217981A1 (https=) |
| MX (1) | MX2023013483A (https=) |
| WO (1) | WO2022241279A2 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004069159A2 (en) * | 2003-01-27 | 2004-08-19 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
| WO2013130776A1 (en) * | 2012-02-29 | 2013-09-06 | Purdue Research Foundation | Folate receptor alpha binding ligands |
| WO2014149069A1 (en) * | 2013-03-15 | 2014-09-25 | Purdue Research Foundation | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
| US20190298843A1 (en) * | 2015-05-11 | 2019-10-03 | Purdue Research Foundation | Ligand ionophore conjugates |
| EP3430383B1 (en) * | 2016-03-16 | 2024-06-26 | On Target Laboratories, LLC | Ca ix-target nir dyes and their uses |
| CN118453888A (zh) * | 2016-11-16 | 2024-08-09 | 普渡研究基金会 | 配体离子载体共轭物 |
| WO2018178936A1 (en) * | 2017-03-30 | 2018-10-04 | Duke University | Radiolabeled biomolecules and their use |
| EP3996715A4 (en) * | 2019-07-08 | 2024-01-03 | Purdue Research Foundation | COMPOUNDS AND METHODS FOR TREATING AND PREVENTING FIBROTIC DISEASES AND CANCER |
-
2022
- 2022-05-13 CA CA3217981A patent/CA3217981A1/en active Pending
- 2022-05-13 AU AU2022271866A patent/AU2022271866A1/en active Pending
- 2022-05-13 JP JP2023570221A patent/JP2024518097A/ja active Pending
- 2022-05-13 WO PCT/US2022/029292 patent/WO2022241279A2/en not_active Ceased
- 2022-05-13 US US18/560,675 patent/US20240335570A1/en active Pending
- 2022-05-13 MX MX2023013483A patent/MX2023013483A/es unknown
- 2022-05-13 EP EP22808452.1A patent/EP4337265A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022241279A3 (en) | 2022-12-22 |
| CA3217981A1 (en) | 2022-11-17 |
| EP4337265A2 (en) | 2024-03-20 |
| WO2022241279A2 (en) | 2022-11-17 |
| AU2022271866A1 (en) | 2023-12-07 |
| US20240335570A1 (en) | 2024-10-10 |
| JP2024518097A (ja) | 2024-04-24 |
| EP4337265A4 (en) | 2026-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000612A (es) | Inmunoconjugados y metodos. | |
| CL2024002388A1 (es) | Agonistas del receptor gpcr, composiciones farmacéuticas y métodos para uso | |
| PH12019501663A1 (en) | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate | |
| NO20066075L (no) | Antistofflegemiddelkonjugater og fremgangsmater | |
| PE20220750A1 (es) | Imidazopirimidinas como inhibidores de eed y uso de estas | |
| AR069788A1 (es) | Formulacion de anticuerpo anti- cd20 humano y usos de la misma | |
| CR10244A (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
| CY1118731T1 (el) | Φαρμακευτικες συνθεσεις αλβιγλουτιδης | |
| CY1116344T1 (el) | Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας | |
| SG149895A1 (en) | Contrast agents for myocardial perfusion imaging | |
| EP1434603A4 (en) | TREATMENT PROCEDURE WITH LIGAND IMMUNOGENIC CONJUGATES | |
| WO2008079973A9 (en) | Egfr binding peptides and uses thereof | |
| EA201690004A1 (ru) | Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение | |
| CO2025001468A2 (es) | Compuestos citotóxicos y conjugados de los mismos | |
| MX2024010601A (es) | Conjugado anticuerpo-farmaco, composicion farmaceutica del mismo y uso del mismo. | |
| BR112022020482A2 (pt) | Combinações antitumor contendo conjugados de anticorpo anti-ceacam5 e folfiri | |
| BR112022013678A2 (pt) | Quelatos macrocíclicos e seus usos | |
| CL2025002617A1 (es) | Conjugados anticuerpo-fármaco administrados por vía subcutánea para el uso en el tratamiento del cáncer | |
| CR20220451A (es) | Moléculas de unión a antígeno anti-cd137 para su administración en el tratamiento contra el cáncer | |
| CO2025009288A2 (es) | Productos terapéuticos dirigidos al receptor de somatostatina subtipo 2 (sst2r) y usos de la misma | |
| GEAP202516674A (en) | Indazole macrocycles and their use | |
| BR112021021728A2 (pt) | Conjugado de anticorpo anti-bcma, composições que compreendem os mesmos e métodos para fazer e usar os mesmos | |
| MX2023013483A (es) | Conjugados blanco del receptor de folato con enlazadores escindibles por la enzima de la membrana en cepillo, y metodos de uso en imagenologia y tratamiento de cancer. | |
| MX2021003295A (es) | Enlazadores basados en sulfomaleimida y sus correspondientes conjugados. | |
| MX2022004341A (es) | Conjugados de fosfolípido-flavaglina y métodos para usar los mismos para la terapia dirigida al cáncer. |